A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation

Interesting activity has been reported by combining chemotherapy with cetuximab. An alternative approach for blocking EGFR function has been the development of small-molecule inhibitors of tyrosine kinase domain such as gefitinib. We designed a multicentre phase II study in advanced colorectal cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Cascinu, S, Berardi, R, Salvagni, S, Beretta, G D, Catalano, V, Pucci, F, Sobrero, A, Tagliaferri, P, Labianca, R, Scartozzi, M, Crocicchio, F, Mari, E, Ardizzoni, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359708/
https://www.ncbi.nlm.nih.gov/pubmed/18059397
http://dx.doi.org/10.1038/sj.bjc.6604121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359708/
https://www.ncbi.nlm.nih.gov/pubmed/18059397
http://dx.doi.org/10.1038/sj.bjc.6604121

Ejemplares similares